BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15288572)

  • 1. Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors.
    Kelley BG; Thayer SA
    Eur J Pharmacol; 2004 Aug; 496(1-3):33-9. PubMed ID: 15288572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AM404 decreases Fos-immunoreactivity in the spinal cord in a model of inflammatory pain.
    Borsani E; Labanca M; Bianchi R; Rodella LF
    Brain Res; 2007 Jun; 1152():87-94. PubMed ID: 17459353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anandamide transport inhibitor AM404 reduces ethanol self-administration.
    Cippitelli A; Bilbao A; Gorriti MA; Navarro M; Massi M; Piomelli D; Ciccocioppo R; Rodríguez de Fonseca F
    Eur J Neurosci; 2007 Jul; 26(2):476-86. PubMed ID: 17650118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent effects of anandamide transporter inhibitors with different target selectivity on social play behavior in adolescent rats.
    Trezza V; Vanderschuren LJ
    J Pharmacol Exp Ther; 2009 Jan; 328(1):343-50. PubMed ID: 18948500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.
    Giuffrida A; Beltramo M; Piomelli D
    J Pharmacol Exp Ther; 2001 Jul; 298(1):7-14. PubMed ID: 11408519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AM404, an inhibitor of anandamide reuptake decreases Fos-immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation.
    Rodella LF; Borsani E; Rezzani R; Ricci F; Buffoli B; Bianchi R
    Eur J Pharmacol; 2005 Jan; 508(1-3):139-46. PubMed ID: 15680264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid activation of recombinant and endogenous vanilloid receptors.
    Ralevic V; Kendall DA; Jerman JC; Middlemiss DN; Smart D
    Eur J Pharmacol; 2001 Jul; 424(3):211-9. PubMed ID: 11672565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide.
    Jonsson KO; Andersson A; Jacobsson SO; Vandevoorde S; Lambert DM; Fowler CJ
    Arch Toxicol; 2003 Apr; 77(4):201-7. PubMed ID: 12698235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anandamide transport inhibitor AM404 activates vanilloid receptors.
    Zygmunt PM; Chuang H; Movahed P; Julius D; Högestätt ED
    Eur J Pharmacol; 2000 May; 396(1):39-42. PubMed ID: 10822052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro.
    Kim SR; Lee DY; Chung ES; Oh UT; Kim SU; Jin BK
    J Neurosci; 2005 Jan; 25(3):662-71. PubMed ID: 15659603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons.
    Guo J; Ikeda SR
    Mol Pharmacol; 2004 Mar; 65(3):665-74. PubMed ID: 14978245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
    Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
    Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations.
    De Lago E; Gustafsson SB; Fernández-Ruiz J; Nilsson J; Jacobsson SO; Fowler CJ
    J Neurochem; 2006 Oct; 99(2):677-88. PubMed ID: 16899063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404.
    Giuffrida A; Rodriguez de Fonseca F; Nava F; Loubet-Lescoulié P; Piomelli D
    Eur J Pharmacol; 2000 Nov; 408(2):161-8. PubMed ID: 11080522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor.
    Beltramo M; de Fonseca FR; Navarro M; Calignano A; Gorriti MA; Grammatikopoulos G; Sadile AG; Giuffrida A; Piomelli D
    J Neurosci; 2000 May; 20(9):3401-7. PubMed ID: 10777802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of anandamide transport inhibitor AM404 on voltage-dependent calcium channels.
    Alptekin A; Galadari S; Shuba Y; Petroianu G; Oz M
    Eur J Pharmacol; 2010 May; 634(1-3):10-5. PubMed ID: 20171208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes.
    Rockwell CE; Kaminski NE
    J Pharmacol Exp Ther; 2004 Nov; 311(2):683-90. PubMed ID: 15284281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of anandamide hypotension by the transport inhibitor, AM404.
    Calignano A; La Rana G; Beltramo M; Makriyannis A; Piomelli D
    Eur J Pharmacol; 1997 Oct; 337(1):R1-2. PubMed ID: 9389389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of receptor types mediating the dilator action of anandamide on blood vessels of the rat knee joint.
    Lam FF; Luk PW; Ng ES
    Life Sci; 2007 Mar; 80(16):1495-502. PubMed ID: 17275857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endogenous cannabinoid anandamide inhibits alpha7 nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes.
    Oz M; Ravindran A; Diaz-Ruiz O; Zhang L; Morales M
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1003-10. PubMed ID: 12766252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.